Literature DB >> 20434717

Intravenous morphine for management of cancer pain.

Sebastiano Mercadante1.   

Abstract

In recent years, a growing interest in palliative care and in routes of administration other than oral have prompted more aggressive measures to improve the efficacy of analgesic interventions in patients with difficult pain conditions. This review provides an overview of the use of intravenous morphine to control pain in patients with cancer. Intravenous morphine has been increasingly used in different clinical situations--including breakthrough pain, poor pain control with escalating doses of oral opioids, retitrating patients with acute pain, treating patients with long-standing poor pain control and unpredictable needs, and optimising opioid therapy to prevent incident pain associated with bone metastases. Although intravenous administration requires supervision, it has considerable advantages, since direct administration into the circulation provides a rapid and predictable effect that is independent of absorption problems. I.v. morphine is advantageous in specific clinical situations and should be part of armamentarium of all physicians treating pain in patients with cancer. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434717     DOI: 10.1016/S1470-2045(09)70350-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  21 in total

1.  Understanding the Chameleonic Breakthrough Cancer Pain.

Authors:  Sebastiano Mercadante; Russell K Portenoy
Journal:  Drugs       Date:  2021-01-30       Impact factor: 9.546

2.  [Neuropathic and tumour-induced headache: Therapeutic options].

Authors:  A Wagner; J A Blunk; J Benrath
Journal:  HNO       Date:  2011-07       Impact factor: 1.284

Review 3.  Options for Treating Pain in Cancer Patients with Dysphagia.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

4.  Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastoma.

Authors:  Martina da Ros; Anna Lisa Iorio; Dario Consolante; Francesco Cardile; Monica Muratori; Ornella Fantappiè; Maurizio Lucchesi; Milena Guidi; Claudio Pisano; Iacopo Sardi
Journal:  Am J Cancer Res       Date:  2016-02-15       Impact factor: 6.166

5.  Spinal activation of delta opioid receptors alleviates cancer-related bone pain.

Authors:  V Otis; P Sarret; L Gendron
Journal:  Neuroscience       Date:  2011-03-31       Impact factor: 3.590

6.  Pituitary Radiosurgery for Management of Intractable Pain: Tokyo Women's Medical University Experience and Literature Review.

Authors:  Mikhail F Chernov; Motohiro Hayashi
Journal:  Acta Neurochir Suppl       Date:  2021

7.  Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Maurizio Ranieri; Antonello Giarratano; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-02-12       Impact factor: 3.603

8.  Mas-related G-protein-coupled receptor c agonist bovine adrenal medulla 8-22 attenuates bone cancer pain in mice.

Authors:  Yu-E Sun; Cui-E Lu; Yishan Lei; Yue Liu; Zhengliang Ma; Xiaoping Gu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

9.  The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

Authors:  Sebastiano Mercadante; Giampiero Porzio; Federica Aielli; Lucilla Averna; Corrado Ficorella; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-04-07       Impact factor: 3.603

10.  Adult cancer pain.

Authors:  Robert A Swarm; Amy Pickar Abernethy; Doralina L Anghelescu; Costantino Benedetti; Sorin Buga; Charles Cleeland; Oscar A Deleon-Casasola; June G Eilers; Betty Ferrell; Mark Green; Nora A Janjan; Mihir M Kamdar; Michael H Levy; Maureen Lynch; Rachel M McDowell; Natalie Moryl; Suzanne A Nesbit; Judith A Paice; Michael W Rabow; Karen L Syrjala; Susan G Urba; Sharon M Weinstein; Mary Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2013-08       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.